Chondrocytes in the epiphyseal cartilage undergo terminal differentiation prior to their removal through apoptosis. To examine the role of ERK1 and ERK2 in chondrocyte terminal differentiation, we generated Osx-Cre; ERK1 
Introduction
In vertebrates, long bones are formed through endochondral ossification, in which chondrocytes undergo a series of proliferation and differentiation processes (1) . This process begins when undifferentiated mesenchymal cells condense and differentiate into chondrocytes. Cells in the chondrocyte lineage then give rise to distinct zones in the epiphyseal cartilage, beginning with the zones of resting chondrocytes, then proliferating chondrocytes, followed by hypertrophic chondrocytes. Chondrocytes in the zones of resting and proliferating chondrocytes express collagen type II (Col2a1), while chondrocytes in the zone of hypertrophic chondrocytes express collagen type X (Col10a1). Further maturation of hypertrophic chondrocytes into terminally differentiated chondrocytes is characterized by the downregulation of Col10a1 and upregulation of terminal differentiation markers Osteopontin and Matrix metalloproteinase-13 (Mmp13), which are also markers of osteoblasts (1) .
Ossification occurs when terminally differentiated chondrocytes undergo apoptosis and the calcified cartilage is invaded by blood vessels along with osteoclasts, osteoblasts, and mesenchymal precursor cells.
The entire process of chondrocyte differentiation is under the concerted regulation by multiple signaling pathways (1) . One of the key signaling pathways involved in these processes is extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK MAPK), which can be activated by various stimuli, including a number of growth factors and cytokines (2) . Various clinical investigations have implicated the critical roles of the ERK MAPK pathway in human skeletal disorders (3) . Our previous studies using genetically engineered mice have also indicated that ERK MAPK signaling plays multiple roles at
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This article is protected by copyright. All rights reserved successive steps of chondrocyte differentiation. Overexpression of a constitutively active mutant of MEK1 in undifferentiated mesenchymal cells inhibited the formation of cartilage anlagen (4) , indicating that ERK MAPK signaling is inhibitory to early chondrocyte differentiation. In addition, the expression of a constitutively active mutant of MEK1 in chondrocytes under the regulatory sequences of Col2a1 inhibited hypertrophic chondrocyte differentiation (5) . The inhibitory effects of ERK MAPK signaling on early chondrocyte differentiation and hypertrophic chondrocyte differentiation have been also demonstrated by ablating ERK1/2 using the Prx1-Cre and Col2a1-Cre transgenes (4) . However, the role of ERK MAPK signaling in the terminal differentiation of hypertrophic chondrocytes requires further investigation. In the current study, we examined the roles of ERK1 and ERK2 in terminal chondrocyte differentiation by inactivating ERK1/2 in hypertrophic chondrocytes using the Osx-Cre transgene, which has been shown to direct Cre recombinase activity in hypertrophic chondrocytes in the growth plate in addition to osteoblasts (6) (7) (8) .
Materials and Methods

Mouse line and breeding
All animal protocols have been approved by the Institutional Animal Care and Use
Committee (IACUC) of Case Western Reserve University. ERK1-null mice (4) , mice with the floxed ERK2 allele (4) , Osx-Cre transgenic mice (6) , and Col1a1CreER-DsRed transgenic mice (9) were described previously. For inducing Cre recombinase activity in Cola1CreER-DsRed embryos, one milligram of tamoxifen (Sigma) dissolved in ethanol and corn oil was injected into the intraperitoneal cavity of the pregnant mother at embryonic day 13.5 (E13.5), E14.5
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Tissue preparation and histological analysis
Skeletal preparations were stained with alcian blue and alizarin red as described (4) . For histology, tissues were fixed in 10% formalin overnight and embedded in paraffin. Postnatal tissues were demineralized in 0.5M EDTA before embedding. Sections were cut in 7 µm and stained with hematoxylin, eosin, and alcian blue, Masson's trichrome stain, or von Kossa's stain using standard protocols. X-gal staining was performed as described previously (10) .
Tartrate-resistant acid phosphatase (TRAP) activity was detected using Acid Phosphatase
Leukocyte kit (Sigma). TRAP-positive cells were counted along the chondro-osseous junction defined as an area between lines 100 m above and 100 m below the junction.
Immunostaining was performed using primary antibodies for von Willebrand factor (vWF) 
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This article is protected by copyright. All rights reserved using the BrdU staining kit (Invitrogen). Cell proliferation was quantified by calculating the ratio of BrdU-labeled chondrocytes relative to total number of chondrocytes in the zones of resting and proliferative chondrocytes. RNA in situ hybridization was done using a digoxigenin-labeled riboprobe (Supplemental Table 1 ). Signal was detected using anti-digoxigenin-alkaline phosphatase (Roche) and NBT/BCIP. All images were taken with a Leica DC500 digital camera with either Leica DM 6000B, DM IRB, or MZ16 microscope using Leica Application Suite 1.3 software.
Quantitative Real-time PCR
The whole tibiae were carefully dissected from E15.5 embryos under a Zeiss Stemi DV4
Stereo microscope. All surrounding connective tissues including perichondrium were removed. Total RNA was extracted using RNeasy kit (Qiagen) and subjected to real-time PCR analysis using TaqMan assays (Applied Biosystems) as described previously (4) . Each reaction was performed in triplicate and repeated on at least three independent samples per genotype.
Plasmids, Cell Culture, and Transient Transfection
OPN(-1206)-luc (11) and pcDNA3-Egr1 (12) were obtained from Addgene. -914/+5 OPN-luc construct was kindly provided by Martha J. Somerman (13) . Egr2 and Nab2 expression plasmids were kind gifts from John Svaren (14) . The cDNA for a constitutively active mutant of MEK1 (S218/222E, Δ32-51) (15) was cloned in pcDNA3.1/Zeo (Invitrogen). Transient transfection experiments were performed in rat chondrosarcoma (RCS) cells (16) using GenJet
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(Promega) and firefly luciferase reporter construct at a 1:99 ratio. Firefly and renilla luciferase activities were assayed with the dual luciferase assay system (Promega) at 48 h after transfection. Firefly luciferase activity was normalized by renilla luciferase activity.
Statistical analysis
Data were calculated from 3-5 independent experiments, and presented as mean ± standard error. Statistical analysis was performed using the student's t-test or one-way analysis of variance. p≤0.05 is considered to be statistically significant.
Results
ERK1/2 inactivation by Osx-Cre delays bone growth
To determine the potential effects of the Osx-Cre transgene per se on bone growth as suggested by other studies (17) , (4) . (Fig.1A, Supplemental Fig 1D) . The long bones of cKO osx mice were significantly shorter than those of control littermates (Fig 1B, Supplemental Fig.1A, B) .
The cKO osx mice invariably died around 3 weeks of age, which may be due to Osx-Cre expression in other systems (18) .
cKO osx mice exhibit delayed formation of primary ossification centers and expansion of the zone of hypertrophic chondrocytes
Histological analysis of the tibia and femur demonstrated that the zone of hypertrophic chondrocytes was consistently wider in the growth plate of cKO osx mice after E15.5. At E15.5, there was no obvious difference in the total bone length and relative proportion of the zone of hypertrophic chondrocytes, indicating that the initial transition from proliferative to hypertrophic chondrocytes is seemingly unaffected in cKO osx mice (Fig.1C) . At E16.5, when the bone marrow cavity was fully developed in control mice, cKO osx mice showed a persistent presence of hypertrophic chondrocytes in the middle of the diaphysis, indicating a delay in the formation of primary ossification centers. While the zone of hypertrophic chondrocytes remained expanded in cKO osx mice from E17.5 through P14, this phenotype gradually normalized after birth, and no difference was noted between cKO osx and control
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This article is protected by copyright. All rights reserved littermate mice at 3 weeks of age (Fig.1C, D) . Despite the delay in the formation of primary ossification centers, cartilage mineralization was not affected in cKO osx mice (Supplemental Fig.2A ). In addition, chondrocyte proliferation was not affected in cKO osx mice (Supplemental Fig.2B ). Histological analysis of 2-week-old mice showed that there was no obvious difference in the development of the secondary ossification centers between cKO osx and control littermate mice (Fig.1E ). The postnatal bone phenotype of cKO osx mice will be further characterized and described elsewhere. Another interesting phenotype in the long bones of cKO osx mice was cartilaginous islands resembling enchondroma in the bone marrow.
The enchondroma-like lesions began to form at about P2 and persisted at least up to 3 weeks of age ( showed abundant cartilage remnants resembling cartilaginous islands in the bone marrow, and these cartilaginous remnants are still connected to the growth plate (Supplemental Fig.1E ). These observations suggest that the cartilaginous islands develop from the unresorbed cartilage.
Expansion of the hypertrophic zone in cKO osx mice is caused by conditional deletion of ERK1 and ERK2 in hypertrophic chondrocytes but not in osteoblasts
Osx-Cre mice have been shown to display Cre recombinase activity both in osteoblasts and hypertrophic chondrocytes in the growth plate (7, 8) . Consistent with previous reports, we observed X-gal staining in hypertrophic chondrocytes as well as cells in the osteoblast lineage in mice harboring the Osx-Cre transgene and the ROSA26-LacZ reporter allele (Fig.2B ). We also examined the inactivation of ERK1/2 in cKO osx mice by
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This article is protected by copyright. All rights reserved immunohistochemistry. While chondrocytes in the resting and proliferating zones showed intense staining in cKO osx mice, staining for ERK1/2 was remarkably reduced in hypertrophic chondrocytes ( Fig.2A) . These observations suggest that the expansion of the zone of hypertrophic chondrocytes in cKO osx mice is caused by ERK1/2 inactivation in hypertrophic chondrocytes. We further inactivated ERK1/2 in osteoblasts by using the Col1a1CreER-DsRed transgene that does not show Cre recombinase activity in chondrocytes (9) . We found no significant difference in the width of the zone of hypertrophic
; ERK2 flox/flox mice compared to controls at E18.5, even though ERK2 was efficiently deleted from osteoblasts in these animals (Fig. 2C ).
These results indicate that ERK1/2 deletion in hypertrophic chondrocytes but not in osteoblasts leads to the expansion of the zone of hypertrophic chondrocytes in cKO osx mice.
Impaired chondrocyte terminal differentiation in cKO osx mice
The expansion of the zone of hypertrophic chondrocytes could be the result of decreased apoptosis, reduced vascular invasion, impaired cartilage resorption, accelerated hypertrophic chondrocyte differentiation, and delayed terminal chondrocyte differentiation. We therefore analyzed chondrocyte apoptosis by TUNEL staining. We found that there was an increase in the number of TUNEL-positive hypertrophic chondrocytes in cKO osx mice (Supplemental Fig.2C ). Since increased apoptosis is expected to result in an opposite phenotype, i.e. the reduction of the zone of hypertrophic chondrocytes, apoptosis is unlikely to account for the expansion of the zone of hypertrophic chondrocytes in cKO osx mice.
The expansion of the zone of hypertrophic chondrocytes may occur through delayed
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Willebrand factor (vWF). At E16.5, immunoreactivity for vWF was restricted to the diaphyseal bone collar in cKO osx mice, correlating with the delayed formation of primary ossification centers in these mice (Supplemental Fig. 3A) . However, at E18.5, when the primary ossification center was formed in cKO osx mice, the pattern of vWF immunostaining at the chondro-osseous junction was indistinguishable between cKO osx mice and control littermates, indicating no major differences in vascular recruitment at this stage (Supplemental Fig. 3B ). We also examined Vegf, an essential regulator of vascular invasion, by in situ hybridization. Vegf expression in hypertrophic chondrocytes was comparable between cKO osx mice and control littermate mice at E18.5 (Supplemental Fig.4A ). These data suggest that impaired angiogenesis is unlikely to be the cause for the expansion of the zone of hypertrophic chondrocytes in cKO osx mice.
Impaired osteoclastogenesis can also lead to the expansion of the zone of hypertrophic chondrocytes. We assessed the number of osteoclasts at the chondro-osseous junction by tartrate-resistant acid phosphatase (TRAP) staining at E18.5 and P7. We found no differences in the number of TRAP positive cells at the chondro-osseous junction between cKO osx and control littermate mice (Supplemental Fig.3D, 3E ). Moreover, immunostaining of Mmp9, a matrix metalloprotease that is highly expressed in osteoclasts/chondroclasts, showed no obvious difference at the chondro-osseous junction between cKO osx and control littermates at E18.5 (Supplemental Fig.3C ). We also examined Rankl and Opg, genes involved in osteoclast differentiation, by quantitative real-time PCR. There was no significant difference
This article is protected by copyright. All rights reserved in Rankl, Opg expression and Rankl/Opg ratio between cKO osx mice and control littermates at E15.5 (Fig.3) . Taken Ihh expression (Fig.4A-C) . In contrast, the expression domain of Col10a1 was expanded at all stages, correlating with the expansion of the zone of hypertrophic chondrocytes.
Furthermore, the area of terminally differentiated chondrocytes, where hypertrophic chondrocytes are past the Col10a1-expressing stage and express Osteopontin and Mmp13, was also expanded in the tibiae of cKO osx mice (Fig.4C) , indicating that the expansion of the zone of hypertrophic chondrocytes was for the most part caused by an increase in the number of terminally differentiated chondrocytes. In addition, Osteopontin and Mmp13 expression in the terminally differentiated chondrocytes was dramatically reduced in cKO osx mice (Fig.4A-C 
This article is protected by copyright. All rights reserved analysis of tibiae at E15.5 (Fig.3, data not shown) . Collectively, these results indicate that in the endochondral bone of cKO osx mice, the terminal differentiation process of early hypertrophic chondrocytes was severely impaired, while chondrocyte differentiation from the proliferative stage to the early hypertrophic stage was unaffected. The impaired terminal differentiation most likely accounts for the expansion of the zone of hypertrophic chondrocytes in cKO osx mice.
ERK1/2 inactivation in hypertrophic chondrocytes likely delays chondrocyte terminal differentiation in part through transcriptional factors Egr1 and Egr2
To identify downstream targets of ERK1/2 in hypertrophic chondrocytes that control terminal differentiation, we examined several candidate transcriptional factors by in situ hybridization and real-time PCR. We found no differences in Runx2 and Sox9 expression between cKO osx and control littermates at E15.5 and E18.5 ( Fig. 3, Supplement Fig.4B , and data not shown).
We also examined immediate early genes such as Egr1 and Egr2 that have been implicated in skeletal development (19) . Real-time PCR analysis indicated that Egr1 and Egr2 were strongly downregulated in the tibiae of cKO osx embryos, and Nab2, a co-repressor of Egr1 and Egr2, was also slightly decreased in these embryos (Fig. 3) . Interestingly, immunohistochemical analysis indicated that the expression of both Egr1 and Egr2 was restricted to hypertrophic chondrocytes adjacent to the chondro-osseous junction (Fig.5A) , indicating co-expression with Osteopontin and Mmp13. Consistent with the real-time PCR results, Egr1 and Egr2 protein levels were strikingly reduced in cKO osx mice compared with control littermates (Fig.5A ).
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To further examine the role of ERK MAPK signaling and Egr1 and Egr2 in terminal chondrocyte differentiation, we tested their effects on the promoter activity of Osteopontin in RCS cells, a chondrocyte cell line derived from rat chondrosarcoma (16) .
Expression of Egr1
and Egr2 increased the activity of OPN (-1206) promotes Osteopontin expression in part through Egr1 and Egr2 (Fig.5C ).
Discussion
During endochondral ossification, chondrocytes undergo sequential steps of differentiation leading to chondrocyte hypertrophy, in which chondrocytes lose Col2a1 expression and initiate Col10a1 expression. Hypertrophic chondrocytes further switch their transcriptional programs and undergo terminal differentiation prior to cell death through apoptosis (1) . During this transition, chondrocytes lose Col10a1 expression and upregulate a new set of genes, including matrix metalloproteinase-13 (Mmp13) and Osteopontin. The precise mechanisms of how this terminal differentiation process takes place remain largely unknown. In the present study, we inactivated ERK1 and ERK2 in hypertrophic chondrocytes using the
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Another interesting phenotype in the long bones of cKO osx mice is enchondroma-like lesions in the bone marrow. These lesions are reminiscent of human metachondromatosis, a human skeletal disorder caused by heterozygous mutations in the PTPN11 gene (33) .
PTPN11
encodes a tyrosine phosphatase SHP2 that promotes ERK MAPK signaling (34) . Postnatal inactivation of Ptpn11 in mice results in the development of metachondromatosis-like exostoses and enchondromas that are characterized by reduced ERK signaling (35, 36) .
Therefore, our observations in cKO osx mice provide strong evidence for the role of reduced ERK signaling in the development of enchondromas in Ptpn11 mutant mice and in human metachondromatosis. Defective terminal differentiation caused by the reduced activity of ERK may account for the development of enchondromas in Ptpn11 mutant mice and in metachondromatosis patients.
There are several weaknesses in the current study. First, we cannot totally rule out the possibility that ERK1/2 inactivation outside of hypertrophic chondrocytes also contributes to the aberrant skeletal growth of cKO osx mice. In this mouse model, ERK1/2 is also inactivated in osteoblasts. In addition, premature lethality of cKO osx mice might be caused by ERK1/2 inactivation elsewhere. The conditional inactivation of ERK1/2 specifically in hypertrophic chondrocytes would be helpful in addressing these possibilities. Second, given the roles of ERK1/2 in lineage specification of osteochondro progenitor cells (4) , aberrant differentiation of osteogenic cells might account for the development of the enchondroma-like lesions in the bone marrow. Third, we were not able to assess the skeletal phenotype in older mice due to
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